Novonesis (Novozymes) B (OTCPK:NVZMF)

$ 60.875 1.133 (1.9%) Market Cap: 28.48 Bil Enterprise Value: 30.18 Bil PE Ratio: 38.65 PB Ratio: 2.42 GF Score: 97/100

Half Year 2024 Novozymes A/S Earnings Call Transcript
Aug 28, 2024

$67.96 (-2.73%)

Earnings
Novozymes A/S 2024 Outlook and 2023 Pro Forma Financials Call Transcript
Mar 21, 2024
Novozymes A/S Extraordinary Shareholders Meeting Transcript
Mar 04, 2024
Q4 2023 Novozymes A/S Earnings Call Transcript
Feb 01, 2024

$53.11 (+3.35%)

Earnings
Q3 2023 Novozymes A/S Earnings Call Transcript
Oct 26, 2023

$42 (+8.11%)

Earnings
Q2 2023 Novozymes A/S Earnings Call Transcript
Aug 09, 2023

$48.92

Earnings
Q1 2023 Novozymes A/S Earnings Call Transcript
Apr 26, 2023

$53.25 (-3.43%)

Earnings
Novozymes A/S Annual Shareholders Meeting Transcript
Mar 02, 2023
Q4 2022 Novozymes A/S Earnings Call Transcript
Jan 26, 2023

$50.86 (+0.48%)

Earnings
Novozymes A/S and Chr Hansen Holding A/S to Discuss Agreement to Combine Through a Statutory Merger Call Transcript
Dec 12, 2022
Q3 2022 Novozymes A/S Earnings Call Transcript
Nov 03, 2022

$50.49 (-1.67%)

Earnings
Q2 2022 Novozymes A/S Earnings Call Transcript
Aug 11, 2022

$59.31

Earnings
Novozymes A/S Spotlight on Human Health Presentation Transcript
Jun 17, 2022
Q1 2022 Novozymes A/S Earnings Call Transcript
Apr 27, 2022

$67.68 (-0.75%)

Earnings
Novozymes A/S Annual Shareholders Meeting Transcript
Mar 16, 2022
Q4 2021 Novozymes A/S Earnings Call Transcript
Feb 01, 2022

$65.7 (-6.06%)

Earnings
Q3 2021 Novozymes A/S Earnings Call Transcript
Oct 27, 2021

$72.38 (-0.51%)

Earnings
Novozymes A/S Capital Markets Day (Virtual) Transcript
Sep 28, 2021
Q2 2021 Novozymes A/S Earnings and to Discuss Investment Into Advanced Protein Solutions Call Transcript
Aug 12, 2021
Q1 2021 Novozymes A/S Earnings Call Transcript
Apr 27, 2021

$73.5 (+8.13%)

Earnings
Novozymes A/S Annual Shareholders Meeting Transcript
Mar 11, 2021
Q4 2020 Novozymes A/S Earnings Call Transcript
Feb 02, 2021

$60.52 (-0.13%)

Earnings
Q3 2020 Novozymes A/S Earnings Call Transcript
Oct 21, 2020

$63.63 (-2.48%)

Earnings
Q2 2020 Novozymes A/S Earnings Call Transcript
Aug 12, 2020

$60.42

Earnings
Q2 2020 Novozymes A/S Trading Update Call Transcript
Jul 08, 2020
Q1 2020 Novozymes A/S Earnings Call Transcript
Apr 29, 2020

$48.9 (+4.40%)

Earnings
Q1 2020 Novozymes A/S Organic Sales Call Transcript
Apr 07, 2020
Novozymes A/S Annual Shareholders Meeting Transcript
Feb 26, 2020
Q4 2019 Novozymes A/S Earnings Call Transcript
Jan 23, 2020

$51.26 (+5.24%)

Earnings
Q3 2019 Novozymes A/S Earnings Call Transcript
Oct 23, 2019

$45 (+4.14%)

Earnings
Novozymes A/S to Discuss the Adjusted FY 2019 Outlook Call Transcript
Oct 10, 2019
Q2 2019 Novozymes A/S Earnings Call Transcript
Aug 08, 2019

$42.88 (-5.84%)

Earnings
Novozymes A/S Capital Markets Day 2019 Transcript
Jun 17, 2019
Q1 2019 Novozymes A/S Earnings Call Transcript
Apr 24, 2019

$46.69 (-2.97%)

Earnings
Novozymes A/S to Discuss the Continuation of Partnership with Bayer AG and with Two New Partners, Univar Solutions and UPL Ltd Call Transcript
Apr 05, 2019
Novozymes A/S Annual Shareholders Meeting Transcript
Feb 27, 2019

Q1 2022 Novozymes A/S Earnings Call Transcript

Apr 27, 2022 / 07:00AM GMT

Release Date Price: $67.68 (-0.75%)

Transcript

Operator

Ladies and gentlemen, welcome to Novozymes' Q1 Conference Call. (Operator Instructions) Today, I am pleased to present Tobias Cornelius Bjorklund, Head of Investor Relations. Dear speakers, please go ahead.

Tobias Cornelius Bjorklund;S;Head of IR

Novozymes A

/-

Thank you very much, operator, and welcome, everyone, to Novozymes' first quarter 2022 conference call. My name is Tobias Bjorklund, and I'm the Head of Investor Relations here at Novozymes.

At this call, our CEO, Ester Baiget; and our CFO, Lars Green, will review our performance and key events in the first quarter as well as the outlook for the full year. Also attending today's call are Tina Fanoe, EVP, Agriculture and Industrial Biosolutions; Amy Byrick, EVP, Strategy and Business Transformation; Anders Lund, EVP, Consumer Biosolutions; and Claus Fuglsang, CSO, EVP of Research and Development. The entire call will last for about 45 minutes, including time for questions at the end.

As always, I would like to remind you that the information presented

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.